Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Candesartan cilexetil/nifedipine - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Candesartan cilexetil/nifedipine - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-98-7106; Candesartan cilexetil/nifedipine GITS; Nifedipine GITS/candesartan cilexetil; Nifedipine/candesartan-cilexetil

Latest Information Update: 28 Aug 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antihypertensives; Benzimidazoles; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Essential hypertension

Most Recent Events

  • 28 Aug 2019 No development reported - Phase-II for Essential hypertension in South Korea, Lithuania, Russia, South Africa, Spain, Ukraine, Argentina, Brazil (PO) (Bayer HealthCare Pharmaceuticals pipeline, August 2019)
  • 28 Aug 2019 No development reported - Phase-III for Essential hypertension in USA, United Kingdom, Germany, Belgium, Canada, Poland, Italy (PO) (Bayer HealthCare Pharmaceuticals pipeline, August 2019)
  • 29 Jan 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top